Dr Connie Guaqueta speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the results from the phase III NALA and SOPHIA trials.

She firstly focuses on the NALA trial, which concluded that neratinib plus capecitabine is a new treatment option for patients with HER2-positive metastatic breast cancer, in comparison to lapatinib plus capecitabine - which is the current standard of care.

Dr Guaqueta also moves on to talk about the SOPHIA trial, which examined the effect of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy. This trial unveiled the activity of margetuximab in this setting, however further data is needed to determine the role of this anti-HER2 antibody, within the current therapeutic landscape.